Context Therapeutics Reports Positive Phase 1 CTIM-76 Data in Ovarian Cancer
CNTX has more than doubled off its 52-week low of $0.56.
Summary
Context Therapeutics announced positive interim Phase 1 clinical trial results for its lead cancer drug candidate, CTIM-76, showing a 29% overall response rate and a favorable safety profile in heavily pre-treated ovarian cancer patients.
Key Events · Product Development and Regulatory · CNTX
-
Positive Phase 1 CTIM-76 Results
Context Therapeutics announced positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, its lead Claudin 6 x CD3 T cell engaging bispecific antibody.
-
Significant Overall Response Rate (ORR)
The trial achieved a 29% confirmed overall response rate (ORR) per RECIST v1.1 in patients with platinum-resistant ovarian cancer (PROC) who had progressed on a median of 7 prior lines of therapy.
-
Favorable Safety Profile
The safety profile was well-tolerated, with Cytokine Release Syndrome (CRS) limited to Grade 1 in only 11% of PROC patients at active dose levels, supporting potential outpatient dosing.
-
Optimized Dosing Schedule
Pharmacokinetic (PK) data supports the exploration of a less frequent, every three weeks (Q3W), dosing schedule in the second half of 2026, potentially enhancing treatment durability and convenience.
Analysis · CNTX · Life Sciences
This filing reports significant positive interim Phase 1 clinical data for Context Therapeutics' lead bispecific antibody, CTIM-76, in platinum-resistant ovarian cancer. The 29% overall response rate in heavily pre-treated patients, combined with a favorable safety profile and low incidence of severe cytokine release syndrome, is a critical de-risking event for the program. This positive clinical update, along with the confirmed cash runway into mid-2027, is crucial for the company's valuation and future financing efforts, especially following recent reports of increased cash burn.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 39.2% of the 344 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTX was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.7M. The 52-week trading range was $0.56 to $3.62. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.